Targeted inhibition (such as gene therapy) to specifically reduce CCDC80 expression in CD8+ cytotoxic T cells, thereby reactivating their antitumor immune activity, has the potential to enhance the response of ovarian cancer patients to ICI treatment. This evidence concerns the gene CCDC80 and ovarian cancer.